There are 140 resources available
83P - Does the most common gynaecological cancer have an awareness blind spot? An Israeli preliminary study
Presenter: Bar Levy
Session: Poster Display
84P - Lack of diversity in clinical trials leading to Food and Drug Administration (FDA) approvals for gynaecological cancers
Presenter: Elena Giudice
Session: Poster Display
85P - Real-world molecular profiling in gynaecologic oncology: Shaping tailored treatments and leveraging genetic insights to provide personalized care
Presenter: Mara Mantiero
Session: Poster Display
87P - Characteristics and prognostic factors of high-grade uterine sarcomas: Unmet need of new therapeutic approaches
Presenter: GIULIA OLIVEIRA
Session: Poster Display
88P - Can we improve the FIGO risk score? Developing the inFIGO score for patients with gestational trophoblastic neoplasia
Presenter: Katia Mercedes Roque Perez
Session: Poster Display
89P - A single-centre retrospective study of patients with brain metastases and gynaecologic cancers
Presenter: Rania Chehade
Session: Poster Display
21O - Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005
Presenter: Alexandra Leary
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
22O - Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study
Presenter: Christophe Le Tourneau
Session: Proffered Paper session
Resources:
Abstract
23O - A randomized, phase III, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for patients enrolled in Asia
Presenter: Yang Xiang
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast